Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATRX loss IDH1 mut |
| Therapy | Gemcitabine + Radiotherapy |
| Indication/Tumor Type | high grade glioma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATRX loss IDH1 mut | high grade glioma | predicted - sensitive | Gemcitabine + Radiotherapy | Phase I | Actionable | In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339). | 26853339 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26853339) | Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study. | Full reference... |